CoLabs
CoLabs International Corp is a pre-launch biotechnology company developing products that reduce unwanted drug absorption through the skin. The Nevada-incorporated firm plans a direct-to-consumer e-commerce launch via its own storefront at colabsintl.com.
- Company typePrivate
- Founded2008
- HeadquartersHuntington Beach, United States
- Headcount1–10
- GTM typeB2C
- OfferingHardware or Manufacturing
What CoLabs does
CoLabs International Corp is a Nevada-incorporated biotechnology company headquartered in Huntington Beach, California, that states its purpose is to offer products reducing the unwanted absorption of drugs into the skin — effectively a topical dermal-barrier technology intended to limit systemic drug uptake. Founded in 2008, the firm remains in a pre-launch commercial phase: its website (colabsintl.com) carries only "Launching Soon" placeholder text, no product catalog, no pricing, and no technology specifications are disclosed in the available sources, and core technology is explicitly listed as "not disclosed" with no patents or trademarks on file.
The company has raised approximately $7.49M across six documented funding events spanning 2013 through 2023, including a $1.5M round in June 2013, a $270K round in January 2018, two larger rounds in early 2021 totaling roughly $5.4M ($2.4M on 2021-01-28 and $3.005M on 2021-02-08), a $315K initial sale from a $600K SEC Form D exempt offering filed 2023-05-23, and an earlier $315K round on 2023-02-24. Investors and lead investors are undisclosed across all rounds. Leadership consists of Founder and CEO Laura Cohen and Co-founder and COO Lisa LeBlanc; the company operates with 1-10 employees.
The planned go-to-market appears to be direct-to-consumer e-commerce through the company's own storefront, evidenced by 'Shop' and 'Cart' pages and a newsletter signup offering 10% off a first purchase. There are no named customers, B2B contracts, distribution partnerships, or revenue figures in the source material, and the company carries no certifications, regulatory clearances (FDA/CE/etc.), or disclosed clinical data. A separate entity referenced as Co.Labs in Saskatchewan received CAD funding from PrairiesCan in April 2026; the source flags this as likely unaffiliated with CoLabs International Corp.
CoLabs firmographics
Firmographics- Name
- CoLabs
- Legal name
- CoLabs International Corp
- Website
- https://colabsintl.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- CoLabs International Corp is a pre-launch biotechnology company developing products that reduce unwanted drug absorption through the skin. The Nevada-incorporated firm plans a direct-to-consumer e-commerce launch via its own storefront at colabsintl.com.
- Ownership category
- akta.pro rank
CoLabs industry classification
Industry- Product category
- Topical Drug Delivery / Consumer Biotechnology
- akta.pro primary industry
- Functional Beverages (Vitamins, Probiotics, Nootropics, etc.) (CRADAHAL)
Keywords
Where CoLabs is headquartered
LocationHeadquarters
- HQ city
- Huntington Beach
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
CoLabs business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
Distribution channels1 record
Marketing channels1 record
CoLabs product offering
Product offeringCore offering
CoLabs develops consumer-facing biotechnology products intended to reduce the unwanted absorption of drugs into the skin. The company plans to distribute these topical barrier products directly to end consumers via its own e-commerce website (colabsintl.com). No specific named SKUs, pricing, or technical specifications are publicly disclosed, and the storefront remains in a "Launching Soon" pre-launch state.
Product overview
CoLabs International Corp operates a website (colabsintl.com) that currently displays only a placeholder 'Launching Soon' page with generic sections for 'Featured Products' and a 'Shop' page. No specific products, services, or named offerings are described in the available sources. The website contains only template placeholder text (e.g., 'Generate excitement', 'Grab interest', 'Feature something') with no actual product catalog, pricing, or service descriptions.
Differentiator
Problem solved
Functional benefit
Companies that use CoLabs
Customer profileIdeal customer profiles1 record
CoLabs technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
CoLabs partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- SEC (Securities and Exchange Commission)minorCoLabs International Corp filed a Form D notice with the SEC for an exempt securities offering of $600,000, involving multiple executives and promoters based in Huntington Beach, California. The initial sale targets $315,000 with a minimum investment of $15,000 per investor.
Scale indicators1 record
Recent moves5 records
Expansion highlights4 records
CoLabs competitors and assessment
Company assessmentDirect peers
- Noven Pharmaceuticals: Noven Pharmaceuticals (a Hisamitsu subsidiary) develops transdermal drug-delivery systems. It is directly comparable to CoLabs because both operate at the intersection of skin and drug absorption, though Noven enables absorption while CoLabs aims to reduce it.
- Crescita Therapeutics: Crescita Therapeutics is a Canadian specialty pharmaceutical company focused on topical drug delivery and skin science. Comparable in scale and topical-pharmaceutical focus, making it a relevant small-cap comparable for CoLabs' planned product category.
- AdhexPharma: AdhexPharma specializes in transdermal drug-delivery patches and topical pharmaceutical systems. Comparable given the shared focus on transdermal/skin drug delivery and pharmaceutical formulation, even though Adhex enables rather than blocks absorption.
- Tapemark: Tapemark is a contract manufacturer specializing in topical and transdermal drug-delivery products. Comparable because its business is built around skin-based pharmaceutical applications and topical formulations — the same product surface area CoLabs is targeting.
Broad incumbents
- Dermavant Sciences: Dermavant Sciences develops and commercializes therapeutics in dermatology. Comparable as a dermatology-focused player working on skin-applied pharmaceutical products, though Dermavant is more developed and focused on delivering therapeutics rather than blocking absorption.
Emerging players
- Aclaris Therapeutics: Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on dermatological and immunological conditions. Comparable as a small-cap dermatology biotech with a similar development-stage profile to CoLabs.
Market position
Strengths3 records
Weaknesses4 records
Competitive moat1 record
Key risks6 records
Key highlights3 records
Customer concentration
CoLabs social profiles
Digital presenceCoLabs financial estimates
Financial estimateRevenue estimate
Valuation estimate
CoLabs leadership team
Management profileNumber of profiles
Profiles2 records
CoLabs funding detail
Funding detailFunding overview
Funding rounds5 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CoLabs M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CoLabs
What does CoLabs do?
CoLabs develops consumer-facing biotechnology products intended to reduce the unwanted absorption of drugs into the skin. The company plans to distribute these topical barrier products directly to end consumers via its own e-commerce website (colabsintl.com). No specific named SKUs, pricing, or technical specifications are publicly disclosed, and the storefront remains in a "Launching Soon" pre-launch state.
Is CoLabs a public or private company?
CoLabs is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was CoLabs founded?
CoLabs was founded in 2008. It employs 1 to 10 people.
Where is CoLabs based?
CoLabs is headquartered in Huntington Beach, United States, in the North America region.
Who are CoLabs's main competitors?
Direct peers on record are Noven Pharmaceuticals, Crescita Therapeutics, AdhexPharma and Tapemark. Dermavant Sciences is listed as a broad incumbent. Aclaris Therapeutics is listed as an emerging player.
Does CoLabs have an API?
No public API is recorded for CoLabs.
What industry is CoLabs in?
CoLabs's product category is Topical Drug Delivery / Consumer Biotechnology. Its primary akta.pro industry code is CRADAHAL, Functional Beverages (Vitamins, Probiotics, Nootropics, etc.).